Nitrite and Nitrosyl Compounds in Food Preservation
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Increased Urinary Nitrate Excretion in Rats with Adjuvant Arthritis
Annals of the Rheumatic Diseases 1994; 53: 547-549 547 Ann Rheum Dis: first published as 10.1136/ard.53.8.547 on 1 August 1994. Downloaded from Increased urinary nitrate excretion in rats with adjuvant arthritis Dirk 0 Stichtenoth, Frank-M Gutzki, Dimitrios Tsikas, Norma Selve, Stefanie M Bode-Boger, Rainer H Boger, Jurgen C Frolich Abstract well established model ofpolyarthritis. For this Objectives-In rats with adjuvant arthritis we applied a recently developed, highly spec measurements were taken of the urinary ific and sensitive gas chromatographic method excretion ofnitrate, reflecting endogenous for determination of nitrite and nitrate in nitric oxide (NO) formation, and cyclic serum, urine, synovia and cell supernatants. guanosine monophosphate (cGMP). NO itself is difficult to measure directly, Methods-Urinary nitrate was deter- because of its very short half life in biological mined by gas chromatography, cGMP by fluids. NO is readily oxidised to nitrite and radioimmunoassay. nitrate,7 which are excreted rapidly into urine. Results-A significant (p < 0.001), more It has been shown, that the major source of than three fold increase of urinary nitrate urinary nitrate, in the absence of excess nitrate excretion was found in rats 20 days after intake in food, is endogenously synthesised induction of adjuvant arthritis compared NO.8 Therefore the NO synthase activity can with non-arthritic rats. There was no be assessed reliably by measuring urinary significant difference in urinary cGMP nitrate excretion, as reported by Suzuki et al9 excretion between arthritic rats and and our group (Bode-Boger et al). control animals. Conclusion-The data suggest that the dramatic increase of urinary nitrate ex- Materials and methods cretion is due to increase of NO synthesis ANIMALS AND ARTHRITIS INDUCTION by the inducible form ofNO synthase. -
(12) United States Patent (10) Patent No.: US 8,569,369 B2 Kramer Et Al
USOO856.9369B2 (12) United States Patent (10) Patent No.: US 8,569,369 B2 Kramer et al. (45) Date of Patent: *Oct. 29, 2013 (54) AMINO ACID COMPOUNDS OTHER PUBLICATIONS (75) Inventors: Ronald Kramer, Phoenix, AZ (US); Jablecka et al., MedSci Monit 10(I):CR29-32 (2004). Alexander Nikolaidis, New Kallikratia Maynard et al., J. Nutr. 131:287-290 (2001). (GR) Ruel et al., J. Thorac Cardiovasc. Surg 135:762-77, 2008. Rytlewski et al., European Journal of Obstetrics & Gynecology and (73) Assignee: Thermolife International, LLC, Reproductive Biology 138:23-28 (2008). Phoenix, AZ (US) Schwedheim et al., Br J Clin Pharmacol 65(1):51-59 (2007). Smith et al., J. Thorac Cardiovasc. Surg 132:58-65 (2006). (*) Notice: Subject to any disclaimer, the term of this Rytlewski et al., Eur J. Clin Invest 35 (1):32-37 (2005). patent is extended or adjusted under 35 Ming et al., Circulation 110:3708-3714 (2004). U.S.C. 154(b) by 0 days. Romero et al., Cardiovascular Drug Reviews 24(3-4):275-290 (2006). This patent is Subject to a terminal dis Oka et al., Vasc Med 10:265-274 (2005). claimer. Hayashi et al., PNAS 102(38): 13681-13686 (2005). Grasemann et al., Eur Respir J 25:62-68 (2005). (21) Appl. No.: 13/468,231 Boger, J. Nutr 137:1650S-1655S (2007). Beghetti et al., J. Thorac Cardiovasc. Surg 132(6): 1501-1502 (2006). (22) Filed: May 10, 2012 Larsen et al., B. Acta Physiol 191(1):59-66 (2007). Berge, Journal of Pharmaceutical Sciences, Jan. 1977, vol. -
Guidance for Identification and Naming of Substance Under REACH
Guidance for identification and naming of substances under 3 REACH and CLP Version 2.1 - May 2017 GUIDANCE Guidance for identification and naming of substances under REACH and CLP May 2017 Version 2.1 2 Guidance for identification and naming of substances under REACH and CLP Version 2.1 - May 2017 LEGAL NOTICE This document aims to assist users in complying with their obligations under the REACH and CLP regulations. However, users are reminded that the text of the REACH and CLP Regulations is the only authentic legal reference and that the information in this document does not constitute legal advice. Usage of the information remains under the sole responsibility of the user. The European Chemicals Agency does not accept any liability with regard to the use that may be made of the information contained in this document. Guidance for identification and naming of substances under REACH and CLP Reference: ECHA-16-B-37.1-EN Cat. Number: ED-07-18-147-EN-N ISBN: 978-92-9495-711-5 DOI: 10.2823/538683 Publ.date: May 2017 Language: EN © European Chemicals Agency, 2017 If you have any comments in relation to this document please send them (indicating the document reference, issue date, chapter and/or page of the document to which your comment refers) using the Guidance feedback form. The feedback form can be accessed via the EVHA Guidance website or directly via the following link: https://comments.echa.europa.eu/comments_cms/FeedbackGuidance.aspx European Chemicals Agency Mailing address: P.O. Box 400, FI-00121 Helsinki, Finland Visiting address: Annankatu 18, Helsinki, Finland Guidance for identification and naming of substances under 3 REACH and CLP Version 2.1 - May 2017 PREFACE This document describes how to name and identify a substance under REACH and CLP. -
Differential Induction of Apoptosis in Swiss 3T3 Cells by Nitric Oxide and the Nitrosonium Cation
Journal of Cell Science 110, 2315-2322 (1997) 2315 Printed in Great Britain © The Company of Biologists Limited 1997 JCS4287 Differential induction of apoptosis in Swiss 3T3 cells by nitric oxide and the nitrosonium cation Shazia Khan1,2, Midori Kayahara1,2, Umesh Joashi2, Nicholas D. Mazarakis2, Catherine Sarraf3, A. David Edwards2, Martin N. Hughes1 and Huseyin Mehmet2,* 1Department of Chemistry, King’s College London, Strand, London WC2R 2LS, UK 2Weston Laboratory, Department of Paediatrics and Neonatal Medicine, and 3Department of Histopathology, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK *Author for correspondence (e-mail: [email protected]) SUMMARY We have investigated the effect of nitric oxide (NO) on decomposition to NO. The apoptotic effect of NO was apoptosis in Swiss 3T3 fibroblasts and compared it to the reduced in the presence of the NO scavenger oxyhaemo- effect of the nitrosonium cation (NO+). Both species globin, or the antioxidants N-acetylcysteine and ascorbic induced apoptosis, confirmed by electron microscopy, acid, whereas in the case of NO+ these antioxidants poten- propidium iodide staining, DNA laddering and activation tiated apoptosis. Glutathione also had a potentiating effect of caspases. The kinetics of triggering apoptosis were on the cytotoxicity of NO+. This suggests that cellular different for the two redox species: NO+ required only a 2 antioxidants may play a role in protecting the cell from NO- hour exposure, whereas NO required 24 hours. Three induced apoptosis while NO+ may trigger apoptosis inde- sources of NO were used: aqueous solutions of NO and two pendently of oxidative stress mechanisms. -
Nitric Oxide Releasing Chelating Agents and Their
Europäisches Patentamt *EP001060174B1* (19) European Patent Office Office européen des brevets (11) EP 1 060 174 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07D 401/12, A61K 31/44 of the grant of the patent: 22.09.2004 Bulletin 2004/39 (86) International application number: PCT/GB1998/003840 (21) Application number: 98962567.8 (87) International publication number: (22) Date of filing: 18.12.1998 WO 1999/033823 (08.07.1999 Gazette 1999/27) (54) NITRIC OXIDE RELEASING CHELATING AGENTS AND THEIR THERAPEUTIC USE STICKSTOFFOXID FREISETZENDE CHELATBILDNER UND IHRE THERAPEUTISCHE VERWENDUNG CHELATEURS LIBERANT DE L’OXYDE NITRIQUE ET LEUR EMPLOI A DES FINS THERAPEUTIQUES (84) Designated Contracting States: (74) Representative: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Hammett, Audrey Grace Campbell et al MC NL PT SE Amersham plc Amersham Place (30) Priority: 23.12.1997 GB 9727226 Little Chalfont, Bucks. HP7 9NA (GB) 13.03.1998 GB 9805450 (56) References cited: (43) Date of publication of application: EP-A- 0 292 761 WO-A-93/20806 20.12.2000 Bulletin 2000/51 WO-A-95/12394 WO-A-96/31217 WO-A-96/39409 WO-A-97/49390 (73) Proprietor: Amersham Health AS US-A- 5 250 550 0401 Oslo (NO) • MOORADIAN D L ET AL: "NITRIC OXIDE (NO) (72) Inventors: DONOR MOLECULES: EFFECT OF NO • TOWART, Robertson RELEASE RATE ON VASCULAR SMOOTH Stoke Poges SL2 4PT (GB) MUSCLE CELL PROLIFERATION IN VITRO" • KARLSSON, Jan, Olof, Gustav JOURNAL OF CARDIOVASCULAR N-1450 Nesoddtangen (NO) PHARMACOLOGY, vol. -
Nitroaromatic Antibiotics As Nitrogen Oxide Sources
Review biomolecules Nitroaromatic Antibiotics as Nitrogen Oxide Sources Review Allison M. Rice, Yueming Long and S. Bruce King * Nitroaromatic Antibiotics as Nitrogen Oxide Sources Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA; Allison M. Rice , Yueming [email protected] and S. Bruce (A.M.R.); King [email protected] * (Y.L.) * Correspondence: [email protected]; Tel.: +1-336-702-1954 Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA; [email protected]: Nitroaromatic (A.M.R.); [email protected] antibiotics (Y.L.) show activity against anaerobic bacteria and parasites, finding * Correspondence: [email protected]; Tel.: +1-336-702-1954 use in the treatment of Heliobacter pylori infections, tuberculosis, trichomoniasis, human African trypanosomiasis, Chagas disease and leishmaniasis. Despite this activity and a clear need for the Abstract: Nitroaromatic antibiotics show activity against anaerobic bacteria and parasites, finding usedevelopment in the treatment of new of Heliobacter treatments pylori forinfections, these conditio tuberculosis,ns, the trichomoniasis, associated toxicity human Africanand lack of clear trypanosomiasis,mechanisms of action Chagas have disease limited and their leishmaniasis. therapeutic Despite development. this activity Nitroaro and a clearmatic need antibiotics for require thereductive development bioactivation of new treatments for activity for theseand this conditions, reductive the associatedmetabolism toxicity can convert -
Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
Review Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Joel Mintz 1,†, Anastasia Vedenko 2,†, Omar Rosete 3 , Khushi Shah 4, Gabriella Goldstein 5 , Joshua M. Hare 2,6,7 , Ranjith Ramasamy 3,6,* and Himanshu Arora 2,3,6,* 1 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA; [email protected] 2 John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] (A.V.); [email protected] (J.M.H.) 3 Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] 4 College of Arts and Sciences, University of Miami, Miami, FL 33146, USA; [email protected] 5 College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA; [email protected] 6 The Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 7 Department of Medicine, Cardiology Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA * Correspondence: [email protected] (R.R.); [email protected] (H.A.) † These authors contributed equally to this work. Abstract: Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumori- Citation: Mintz, J.; Vedenko, A.; genic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the Rosete, O.; Shah, K.; Goldstein, G.; level of production, the oxidative/reductive (redox) environment in which this radical is generated, Hare, J.M; Ramasamy, R.; Arora, H. -
WL-13 Safety Data Sheet, Canada (SDS-WL-13-CA
WL- 13 Safety Data Sheet according to the Hazardous Products Regulation (February 11, 2015) SECTION 1: Identification 1.1. Product identifier Product form : Mixture Product name : WL- 13 1.2. Recommended use and restrictions on use No additional information available 1.3. Supplier Swagelok Supplier: 29495 F.A. Lennon Drive Distributor, add your contact information 44139 Solon, OH - United States T 440-349-5600 - F 440-519-3304 www.swagelok.com 1.4. Emergency telephone number Emergency number : Infotrac: North America: 1-800-535-5053 International: 1-352-323-3500 SECTION 2: Hazard identification 2.1. Classification of the substance or mixture Classification (GHS-CA) Not classified 2.2. GHS Label elements, including precautionary statements GHS-CA labeling No labeling applicable 2.3. Other hazards No additional information available 2.4. Unknown acute toxicity (GHS-CA) No data available SECTION 3: Composition/Information on ingredients 3.1. Substances Not applicable 3.2. Mixtures Name Chemical name / Synonyms Product identifier % Classification (GHS-CA) Molybdenum(IV) sulfide Molybdenum disulfide / Molybdenum (CAS-No.) 1317-33-5 <= 10 Comb. Dust disulphide / Molybdenum sulfide / Molybdenum sulfide (MoS2) / Manganese tetroxide Sodium nitrite Diazotizing salts / Nitrous acid, (CAS-No.) 7632-00-0 <= 1.8 Acute Tox. 3 (Oral), H301 sodium salt / Nitrous acid, sodium Aquatic Acute 1, H400 salt (1:1) / SODIUM NITRITE Full text of hazard classes and H-statements: see section 16 SECTION 4: First-aid measures 4.1. Description of first aid measures First-aid measures after inhalation : Allow victim to breathe fresh air. Allow the victim to rest. First-aid measures after skin contact : Remove affected clothing and wash all exposed skin area with mild soap and water, followed by warm water rinse. -
Nitric Oxide Activates Guanylate Cyclase and Increases Guanosine 3':5'
Proc. Natl. Acad. Sci. USA Vol. 74, No. 8, pp. 3203-3207, August 1977 Biochemistry Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations (nitro compounds/adenosine 3':5'-cyclic monophosphate/sodium nitroprusside/sodium azide/nitrogen oxides) WILLIAM P. ARNOLD, CHANDRA K. MITTAL, SHOJI KATSUKI, AND FERID MURAD Division of Clinical Pharmacology, Departments of Medicine, Pharmacology, and Anesthesiology, University of Virginia, Charlottesville, Virginia 22903 Communicated by Alfred Gilman, May 16, 1977 ABSTRACT Nitric oxide gas (NO) increased guanylate cy- tigation of this activation. NO activated all crude and partially clase [GTP pyrophosphate-yase (cyclizing), EC 4.6.1.21 activity purified guanylate cyclase preparations examined. It also in- in soluble and particulate preparations from various tissues. The effect was dose-dependent and was observed with all tissue creased cyclic GMP but not adenosine 3':5'-cyclic monophos- preparations examined. The extent of activation was variable phate (cyclic AMP) levels in incubations of minces from various among different tissue preparations and was greatest (19- to rat tissues. 33-fold) with supernatant fractions of homogenates from liver, lung, tracheal smooth muscle, heart, kidney, cerebral cortex, and MATERIALS AND METHODS cerebellum. Smaller effects (5- to 14-fold) were observed with supernatant fractions from skeletal muscle, spleen, intestinal Male Sprague-Dawley rats weighing 150-250 g were decapi- muscle, adrenal, and epididymal fat. Activation was also ob- tated. Tissues were rapidly removed, placed in cold 0.-25 M served with partially purified preparations of guanylate cyclase. sucrose/10 mM Tris-HCl buffer (pH 7.6), and homogenized Activation of rat liver supernatant preparations was augmented in nine volumes of this solution by using a glass homogenizer slightly with reducing agents, decreased with some oxidizing and Teflon pestle at 2-4°. -
Acids and Bases
Name Date Class CHAPTER 14 REVIEW Acids and Bases SECTION 1 SHORT ANSWER Answer the following questions in the space provided. 1. Name the following compounds as acids: sulfuric acid a. H2SO4 sulfurous acid b. H2SO3 hydrosulfuric acid c. H2S perchloric acid d. HClO4 hydrocyanic acid e. hydrogen cyanide 2. H2S Which (if any) of the acids mentioned in item 1 are binary acids? 3. Write formulas for the following acids: HNO2 a. nitrous acid HBr b. hydrobromic acid H3PO4 c. phosphoric acid CH3COOH d. acetic acid HClO e. hypochlorous acid 4. Calcium selenate has the formula CaSeO4. H2SeO4 a. What is the formula for selenic acid? H2SeO3 b. What is the formula for selenous acid? 5. Use an activity series to identify two metals that will not generate hydrogen gas when treated with an acid. Choose from Cu, Ag, Au, Pt, Pd, or Hg. 6. Write balanced chemical equations for the following reactions of acids and bases: a. aluminum metal with dilute nitric acid ϩ → ϩ 2Al(s) 6HNO3(aq) 2Al(NO3)3(aq) 3H2(g) b. calcium hydroxide solution with acetic acid ϩ → ϩ Ca(OH)2(aq) 2CH3COOH(aq) Ca(CH3COO)2(aq) 2H2O(l ) MODERN CHEMISTRY ACIDS AND BASES 117 Copyright © by Holt, Rinehart and Winston. All rights reserved. Name Date Class SECTION 1 continued 7. Write net ionic equations that represent the following reactions: a. the ionization of HClO3 in water ϩ → ϩ ϩ Ϫ HClO3(aq) H2O(l ) H3O (aq) ClO3 (aq) b. NH3 functioning as an Arrhenius base ϩ → ϩ ϩ Ϫ NH3(aq) H2O(l ) ← NH4 (aq) OH (aq) 8. -
Mechanisms of Nitric Oxide Reactions Mediated by Biologically Relevant Metal Centers
Struct Bond (2014) 154: 99–136 DOI: 10.1007/430_2013_117 # Springer-Verlag Berlin Heidelberg 2013 Published online: 5 October 2013 Mechanisms of Nitric Oxide Reactions Mediated by Biologically Relevant Metal Centers Peter C. Ford, Jose Clayston Melo Pereira, and Katrina M. Miranda Abstract Here, we present an overview of mechanisms relevant to the formation and several key reactions of nitric oxide (nitrogen monoxide) complexes with biologically relevant metal centers. The focus will be largely on iron and copper complexes. We will discuss the applications of both thermal and photochemical methodologies for investigating such reactions quantitatively. Keywords Copper Á Heme models Á Hemes Á Iron Á Metalloproteins Á Nitric oxide Contents 1 Introduction .................................................................................. 101 2 Metal-Nitrosyl Bonding ..................................................................... 101 3 How Does the Coordinated Nitrosyl Affect the Metal Center? .. .. .. .. .. .. .. .. .. .. .. 104 4 The Formation and Decay of Metal Nitrosyls ............................................. 107 4.1 Some General Considerations ........................................................ 107 4.2 Rates of NO Reactions with Hemes and Heme Models ............................. 110 4.3 Mechanistic Studies of NO “On” and “Off” Reactions with Hemes and Heme Models ................................................................................. 115 4.4 Non-Heme Iron Complexes .......................................................... -
Nitrosamines EMEA-H-A5(3)-1490
25 June 2020 EMA/369136/2020 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation EC (No) 726/2004 Nitrosamine impurities in human medicinal products Procedure number: EMEA/H/A-5(3)/1490 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ...................................................................................... 2 1. Information on the procedure ............................................................... 7 2. Scientific discussion .............................................................................. 7 2.1. Introduction......................................................................................................... 7 2.2. Quality and safety aspects ..................................................................................... 7 2.2.1. Root causes for presence of N-nitrosamines in medicinal products and measures to mitigate them............................................................................................................. 8 2.2.2. Presence and formation of N-nitrosamines